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A protective effect of female sex hormones has been suggested to explain the male predominance in esophageal and gastric adeno-
carcinoma, but evidence is lacking. We aimed to test whether menopausal hormone therapy (MHT) decreases the risk of these
tumors. For comparison, esophageal squamous cell carcinoma was also assessed. This population-based matched cohort study
included all women who had ever used systemic MHT in Sweden in 2005–2012. A comparison cohort of non-users of MHT was
matched to the MHT-users regarding age, parity, thrombotic events, hysterectomy, diabetes, obesity, smoking-related diseases and
alcohol-related diseases. Individuals with any previous cancer were excluded. Data on MHT use, cancer, comorbidity and mortality
were collected from well-established Swedish nationwide registers. Odds ratios (OR) with 95% confidence intervals (CI) were calcu-
lated using conditional logistic regression. Different MHT regimens and age groups were compared in sub-group analyses. We iden-
tified 290,186 ever-users and 870,165 non-users of MHT. Ever-users had decreased ORs of esophageal adenocarcinoma (OR50.62,
95% CI 0.45–0.85, n546), gastric adenocarcinoma (OR50.61, 95% CI 0.50–0.74, n5123) and esophageal squamous cell carci-
noma (OR50.57, 95% CI 0.39–0.83, n533). The ORs were decreased for both estrogen-only MHT and estrogen and progestin
combined MHT, and in all age groups. The lowest OR was found for esophageal adenocarcinoma in MHT-users younger than 60
years (OR50.20, 95% CI 0.06–0.65). Our study suggests that MHT-users are at a decreased risk of esophageal and gastric adeno-
carcinoma and also of esophageal squamous cell carcinoma. The mechanisms behind these associations remain to be elucidated.
The explanation for the intriguing male predominance in
esophageal and gastric adenocarcinoma might provide impor-
tant clues to the etiology of these tumors and also pave the
way for research examining novel preventive and therapeutic
medication.1 The up to 9-fold higher risk of esophageal ade-
nocarcinoma among men than in women, is not explained
by the sex distribution of its main risk factors, i.e., gastro-
esophageal reﬂux disease and obesity.1–5 For gastric adeno-
carcinoma, the incidence is 2-fold higher in men, a difference
that is also not readily explained by the major risk factors,
i.e., Helicobacter pylori infection and tobacco smoking.6–8
The 3-fold higher incidence of esophageal squamous cell car-
cinoma in men is mainly explained by the sex distribution of
its main risk factors, i.e., heavy use of tobacco and alcohol.9,10
Female sex hormones may prevent esophageal and gastric
adenocarcinoma.1,6 However, studies examining various sex
hormone related exposures in relation to risk of these tumors
have provided conﬂicting results.1,6,11 Menopausal hormone
therapy (MHT), also known as hormone replacement thera-
py, consists of estrogen or estrogen combined with progestin.
Original studies examining MHT and risk of esophageal and
gastric adenocarcinoma have typically been under-powered,
have mostly examined one or two cancers per study and
arrived at inconsistent ﬁndings.1,11 However, meta-analyses
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comparing ever-users of MHT with non-users have shown
statistically signiﬁcantly decreased relative risk estimates of
esophageal adenocarcinoma, gastric adenocarcinoma and also
of esophageal squamous cell carcinoma.12–14 We hypothe-
sized that MHT decreases the risk of esophageal and gastric
adenocarcinoma, but not of esophageal squamous cell carci-
noma. To test this hypothesis and address the limitations of
the available literature, we conducted a large and population-
based study enabling a possibility of comparing the risks of
all three cancers in one study.
Patients and Methods
Design
This was a population-based matched cohort study based on
prospectively collected data from well-established nationwide
Swedish registers, comparing the risk of esophageal and gas-
tric cancer in all women residing in Sweden exposed to sys-
temic MHT with that of women not exposed to MHT. Entry
into the cohort was between July 1, 2005 and December 31,
2012. Follow-up for both the users and non- users was until
a diagnosis of cancer, death, or December 31, 2012, whichev-
er occurred ﬁrst. The non-users of MHT were frequency-
matched to the ever-users on potential confounding factors.
Eligible were only women 40 years or older without any
previous cancer. The study was approved by the Regional
Ethical Review Board in Stockholm, Sweden (number 2014/
1291–31/4).
Data sources
The Swedish Prescribed Drug Registry was used to identify all
individuals receiving MHT during the study period. This reg-
ister started in July 1, 2005 and collects data on all prescribed
and dispensed drugs in Sweden, including the names of med-
ications, Anatomical Therapeutic Chemical classiﬁcation sys-
tem (ATC) codes, and the dates that treatments were
dispensed. Using the unique 10-digit personal identity num-
ber, assigned to all Swedish residents upon birth or immigra-
tion, all included women were linked to the Swedish Cancer
Registry, Patient Registry and the Causes of Death Registry.15
The Swedish Cancer Registry contains data on all malig-
nant tumors diagnosed in Sweden since 1958. The informa-
tion includes date of diagnosis, anatomical site and
histological type of each tumor. The register has 98% nation-
wide completeness regarding both esophageal and gastric
cancer,16,17 and the recording of all cancer sites is 96% com-
plete.18 This register was used to identify esophageal and gas-
tric cancer during follow-up of the ever-users and non-users
of MHT and to exclude individuals with a history of any pre-
vious cancer.
The Swedish Patient Registry contains information regard-
ing diagnoses and surgical procedures in all in-patient care
and specialist out-patient care in Sweden. The register was
founded in 1964, and data regarding in-patient care and out-
patient specialist care has been 100% nationwide complete
since 1987 and 2001, respectively.19 The validity of the
recording of all diagnoses and gynecological surgical proce-
dures is excellent.19,20 The registry was used to identify
comorbidities used in the matching and statistical analyses.
Data regarding comorbidities were retrieved since the initia-
tion of the Patient Registry to improve ascertainment and
validity of comorbidities.
The Swedish Causes of Death Registry contains data on
date of death and causes of death of all Swedish residents
since 1952. The registry has an overall 100% completeness
regarding date of death and 99.2% completeness for cause-
speciﬁc death.21 This register was used to assess mortality.
Exposure
The MHT-exposed cohort included all women, above 40
years of age without a history of any cancer, who were ever
prescribed and dispensed systemic MHT during the study
period. MHT exposure was deﬁned according to the follow-
ing ATC-codes: G03C (estrogens); G03D (progestogens, only
included if prescribed in combination with estrogens); and
G03F (progestogens and estrogen in combination). MHT is
used for treatment of menopausal symptoms and prevention
of osteoporosis and is recommended as estrogen combined
with progestin in women with an intact uterus (to reduce the
risk of endometrial cancer) or as estrogen alone in women
who have undergone hysterectomy.22–24 Only systemic treat-
ments were included, i.e., oral tablets, dermal patches and
dermal gel.
The non-exposed comparison cohort consisted of women
not receiving a prescription of MHT during the study period,
older than 40 years and without a history of any cancer. The
non-exposed women were selected from the nationwide che-
moprevention cohort, which includes up to 95% of all wom-
en in Sweden of this age group. These participants were
What’s new?
Men carry an up to 9-fold higher risk to develop esophageal adenocarcinoma than women. Here the authors used menopausal
hormonal therapy as a way to assess the impact of female sex hormone exposure on esophageal and gastric cancer risk. Their
data show that women who have ever used menopausal hormone therapy were protected from esophageal and gastric
adenocarcinoma as well as esophageal squamous cell carcinoma regardless if estrogen only or combined estrogen and pro-
gestin therapies were used. These results underscore a protective role of female sex hormones in the development of these
cancers.
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frequency-matched to mimic the MHT-users on the distribu-
tion of the variables age, parity, hysterectomy, thrombotic
events, diabetes, obesity, smoking-related diseases and
alcohol-related diseases.
Outcomes
Esophageal cancer was identiﬁed using the International
Classiﬁcation of Diseases version 7 (ICD-7) anatomical codes
150 (esophagus) or 1511 (cardia) and histological codes 096
for adenocarcinoma and 146 for squamous cell carcinoma in
the Cancer Register. Gastric cancer was identiﬁed using the
ICD-7 anatomical codes 1510, 1518 or 1519, and the histo-
logical code 096 was used only to deﬁne adenocarcinoma.25
Patients with unspeciﬁed histological types of cancer were
excluded from the analyses.
Confounders
Ten potential confounding factors were considered. First, we
included only participants without a history of any cancer (to
avoid bias from detection or inﬂuence of cancer treatments).
The ever-users of MHT were matched to the non-users to
select a group of non-users as similar as possible to the users
regarding eight a priori selected factors. Group-level (i.e., fre-
quency) matching was used, aiming for a 1:3 ratio with exact
matching on three binary variables: parity (ever-parous or
non-parous, increased life time exposure to estrogen), hyster-
ectomy (leading to earlier contact with gynecologist, and
inﬂuencing the choice of what MHT treatment to use) and
thrombotic events (contraindication for MHT).26 Nearest
neighbor matching was done for another ﬁve variables: age (a
risk factor for cancer, determined from exact date of birth),
diabetes mellitus (a proxy for obesity), obesity (which might
inﬂuence the probability of receiving MHT, and is a risk fac-
tor for the studies cancers), smoking-related diseases (a proxy
for smoking, which might inﬂuence both the probability of
receiving MHT and the cancer risk) and alcohol-related dis-
eases (a proxy for high alcohol consumption, which might
inﬂuence both the probability of receiving MHT and the can-
cer risk).26 The used matching method aims for as close to
an exact match on all the included variables to reduce base-
line imbalances. Finally, after the matching procedure was
completed, osteoporosis was added and adjusted for in the
analysis (since this is an indication for treatment with
MHT).23 All codes deﬁning the comorbidities are presented
in the Supporting Information Table 1. If an individual
lacked a certain diagnosis code, this diagnosis was interpreted
as absent.
Statistical analysis
The cancer risk was assessed in a conditional logistic regres-
sion model, taking into account the clustering by the exact
matching variables, as well as also adjusting for all the poten-
tial confounders. Due to the study design, follow-up time for
the non-users is not calculated, nor used in the analyses. The
results were presented as odds ratios (OR) with 95%
conﬁdence intervals (CI). Subgroup analyses were conducted
based on the regimen of MHT (estrogen only or estrogen
combined with progestin) and age groups (year of birth
before 1943, 1943–1951, or in 1952 or later). The age groups
were deﬁned based on the recommended ages for MHT use,
i.e., recommended for women aged younger than 60 years
and not recommended for women aged older than 70 years.27
Poisson regression was conducted when comparing 12
months duration of MHT treatment with >12 months
duration.
Results
Participants
The study included 290,186 ever-users of MHT and 870,165
matched non-users of MHT. Of the ever-users, 135,988
(46.9%) dispensed estrogen only MHT and 154,198 (53.1%)
dispensed a combination of estrogen and progestin MHT.
The ever-users and non-users were similar regarding the
prevalence of all matching variables (Table 1). The median
follow-up time among the users of MHT was 7.0 years (2540
days), and the interquartile range was 4.1–7.4 years (1487–
2685 days).
Risk of esophageal adenocarcinoma
Among the ever-users of MHT, 46 (0.02%) developed esoph-
ageal adenocarcinoma, while 224 (0.03%) such cases occurred
among non-users (Table 1). The adjusted OR of esophageal
adenocarcinoma was 38% lower among ever-users compared
to non-users (OR 0.62, 95% CI 0.45–0.85) (Table 2). Among
users of estrogen only MHT, the corresponding OR was 0.57
(95% CI 0.37–0.87), while the OR among women receiving
estrogen and progestin combined MHT was 0.70 (95% CI
0.45–1.09). In MHT-users younger than 60 years, the OR of
esophageal adenocarcinoma was particularly decreased (OR
0.20, 95% CI 0.06–0.65), while the ORs were less decreased
in MHT-users aged 60–70 years (OR 0.60, 95% CI 0.34–1.07)
and those older than 70 years (OR 0.79, 95% CI 0.52–1.19)
(Table 3). The statistical power was insufﬁcient to allow anal-
yses examining duration of MHT.
Risk of gastric adenocarcinoma
There were 123 (0.04%) new cases of gastric adeoncarcinoma
among the ever-users of MHT and 608 (0.07%) cases among
the non-users (Table 1). Comparing ever-users with non-
users, the overall adjusted OR of gastric adenocarcinoma was
0.61 (95% CI 0.50–0.74) (Table 2). Ever-users of estrogen
only MHT (OR 0.60, 95% CI 0.47–0.76) and of estrogen and
progestin combined MHT (OR 0.64, 95% CI 0.48–0.87) had
decreased ORs of similar strength. The OR of gastric adeno-
carcinoma was particularly decreased in MHT-users younger
than 60 years (OR 0.39, 95% CI 0.21–0.71) and less so in
those of 60–70 years of age (OR 0.69, 95% CI 0.48–0.98) and
in MHT-users older than 70 years (OR 0.63, 95% CI 0.49–
0.81) (Table 3). When comparing 12 months duration of
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MHT with >12 months the incidence rate ratio was 0.92
(95% CI 0.43–1.97).
Risk of esophageal squamous cell carcinoma
Among the ever-users of MHT, 33 (0.01%) developed esoph-
ageal squamous cell carcinoma, while 174 (0.02%) of the
non-users developed this cancer. The overall adjusted OR of
esophageal squamous cell carcinoma was 43% decreased
among ever-users (OR 0.57, 95% CI 0.39–0.83) (Table 2).
The OR among women receiving estrogen only MHT was
0.71 (95% CI 0.46–1.09) and 0.38 (95% CI 0.19–0.75) among
women receiving estrogen and progestin combined (Table 2).
The OR was 0.80 (95% CI 0.26–2.44) in MHT-users younger
than 60 years, 0.41 (95% CI 0.20–0.82) in users aged 60–70
years and 0.65 (95% CI 0.40–1.05) in MHT-users older than
70 years (Table 3). Comparing duration 12 months with
>12 months, of MHT treatment rendered an incidence rate
ratio of 0.45 (95% CI 0.11–1.79).
Discussion
In this study, ever-users of MHT were at a decreased risk of
esophageal adenocarcinoma, gastric adenocarcinoma and
esophageal squamous cell carcinoma. The estrogen only
MHT-users had a decreased risk of esophageal and gastric
adenocarcinoma in particular, while women using combined
therapy with estrogen and progestin may be at a particularly
decreased risk of esophageal squamous cell carcinoma. For
esophageal and gastric adenocarcinoma, a strongly decreased
risk following MHT use was found among younger women.
Strengths of this study include the complete nationwide
coverage with a large sample size, the completeness of the
follow-up, and the validity of the data contained in the Swed-
ish registers used. The linkage of data between registers using
the personal identity numbers available in all Swedish resi-
dents was a prerequisite for this study.15 The Prescribed
Drug Registry contains all prescribed and dispensed medica-
tions in Sweden, thus minimizing the risk of selection bias.
The completeness and accuracy of the data in the Cancer
Registry guarantees a robust assessment of the study out-
comes.16–18 There are, however, also limitations of the study.
Confounding is a threat to observational studies in general.
We could not take into account potential inﬂuence of breast-
feeding and other reproductive factors, including age at men-
opause or number of pregnancies and deliveries, factors that
may affect the lifetime cumulative estrogen exposure. There
is also a possibility that women using MHT differ from
women not having such treatment in terms of lifestyle factors
that in turn affect the risk of the studied cancers. However,
the study controlled for 10 potential confounders which
should have counteracted confounding, which creates a
Table 1. Characteristics of ever-users and non-users of menopausal hormone therapy (MHT)
Ever-users of MHT Non-users of MHT
Number (%) Number (%)
Total 290,186 (100.0) 870,165 (100.0)
Age (in years)
<60 108,631 (37.4) 325,747 (37.4)
60–69 93,490 (32.2) 267,323 (30.8)
70 88,065 (30.4) 277,095 (31.8)
Follow-up (years)
Median (Interquartile range) 7.0 (4.1–7.4) N/A
Parity
Ever-parous 117,861 (40.6) 353,282 (40.6)
Comorbidity
Hysterectomy 51,811 (17.9) 155,138 (17.8)
Thrombotic events 40,316 (13.9) 120,931 (13.9)
Diabetes mellitus 15,936 (5.5) 48,422 (5.6)
Obesity 5,146 (1.8) 15,526 (1.8)
Smoking-related diseases 13,601 (4.7) 40,994 (4.7)
Alcohol-related diseases 7,293 (2.5) 21,455 (2.5)
Osteoporosis 8,256 (2.9) 22,764 (2.6)
Esophageal or gastric cancer during follow-up
Esophageal adenocarcinoma 46 (0.02) 224 (0.03)
Esophageal squamous cell carcinoma 33 (0.01) 174 (0.02)
Gastric adenocarcinoma 123 (0.04) 608 (0.07)
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comparison group as similar as possible to the exposed group
at baseline. The matching on key factors mimics a randomi-
zation on the selected factors. Since some of the confounding
factors were recorded to only a limited degree in the regis-
ters, e.g., obesity and diabetes, the matching strategy is ideal.
No validation study of obesity diagnosis in the Swedish
Patient Registry has been conducted till today, although obe-
sity is believed to be substantially underreported. The coding
for diabetes mellitus (type 1 and 2) in the Swedish Patient
Registry has been found to have high validity in previous
studies.20 Smoking and alcohol consumption were assessed
indirectly, based on smoking-related diseases and alcohol-
related diseases. Although this does not represent the true
incidence of smoking and excessive alcohol consumption, it
should detect the most severe and long-term consumers. We
did not adjust for gastroesophageal reﬂux disease or Helico-
bacter pylori, the risk factors for esophageal adenocarcinoma
and gastric adenocarcinoma, respectively.1,7 However, estro-
gen therapy is rather associated with an increased risk of
reﬂux and could therefore not explain the negative associa-
tion between MHT and esophageal adenocarcinoma.28 MHT
use is unlikely to be associated with Helicobacter pylori and
thus should not act as a confounder.29 A weakness was the
lack of starting dates of MHT use for women enrolled in the
cohort in July 2005 (start of the study), which prohibited an
assessment of duration of MHT use in relation to cancer
risk. The lack of information on MHT use before 2005
resulted in a possibility that women might have received
MHT before the initiation of the study, which could lead to
women using MHT before the initiation of the registration
were included in the non-exposed cohort. However, such
exposure misclassiﬁcation is likely to be at random and
would thus dilute the ORs rather than explaining the
decreased ORs. Further, due to the current design and statis-
tical analyses a sensitivity analysis is not possible since no
proxy date of entry is assigned to the non-users, meaning
that only cases among users can be excluded from the ﬁrst
year of inclusion in the study. Finally, a longer follow-up
than about 8 years would have been preferable when study-
ing cancer risk. Yet the study is the largest cohort
investigating the association between MHT and risk of
esophageal and gastric cancer.
The study hypothesis was based on the unexplained
strong male predominance in esophageal adenocarcinoma
and moderate male predominance in gastric adenocarcinoma,
which we thought would be reﬂected in a reduced risk
among MHT-users. We thought the already explained male
predominance in esophageal squamous cell carcinoma, would
transfer into no association with MHT use. We cannot
entirely exclude that the reduction in the risk of all three
cancers may indicate healthy users bias, a sampling bias
where patients receiving MHT might differ from the compar-
ison population, mainly differences in lifestyle behavior. This
could among other things be in relation to smoking and alco-
hol consumption, where there might be differences between
different age groups, which could reﬂect in the different ORs
Table 3. The risk of esophageal and gastric cancers in ever-users of
menopausal hormone therapy (MHT) compared to non-users, catego-
rized by age group and expressed as odds ratios (OR) with 95% con-
fidence intervals (CI)
Ever-users
Number (%)
Non-users
Number (%) OR (95% CI)1
Esophageal adenocarcinoma
<60 years 3 (0.00) 43 (0.01) 0.20 (0.06–0.65)
60–69 years 14 (0.01) 67 (0.03) 0.60 (0.34–1.07)
70 years 29 (0.03) 14 (0.00) 0.79 (0.52–1.19)
Gastric adenocarcinoma
<60 years 12 (0.01) 89 (0.03) 0.39 (0.21–0.71)
60–69 years 37 (0.04) 153 (0.06) 0.69 (0.48–0.98)
70 years 74 (0.08) 366 (0.13) 0.63 (0.49–0.81)
Esophageal squamous cell carcinoma
<60 years 4 (0.00) 14 (0.00) 0.80 (0.26–2.44)
60-69 years 9 (0.00) 63 (0.02) 0.41 (0.20–0.82)
70 years 20 (0.02) 97 (0.04) 0.65 (0.40–1.05)
1Adjusted for age, parity, hysterectomy, thrombotic events, diabetes
mellitus, obesity, smoking-related diseases, alcohol-related diseases
and osteoporosis (all but osteoporosis were used for matching.
Table 2. The risk of esophageal and gastric cancers following ever use of different regimens of menopausal hormone therapy (MHT) compared
to non-users, expressed as odds ratios (OR) with 95% confidence intervals (CI)
Non-users
Number5870,165
Ever-users
Number5290,186
Estrogen only users
Number5135,988
Estrogen1 progestin users
Number5154,198
Number (%)
Number
(%)
OR (95%
CI)1
Number
(%)
OR (95%
CI)1
Number
(%)
OR (95%
CI)1
Esophageal adenocarcinoma 224 (0.03) 46 (0.02) 0.62 (0.45–0.85) 24 (0.02) 0.57 (0.37–0.87) 22 (0.01) 0.70 (0.45–1.09)
Gastric adenocarcinoma 608 (0.07) 123 (0.04) 0.61 (0.50–0.74) 75 (0.06) 0.60 (0.47–0.76) 48 (0.03) 0.64 (0.48–0.87)
Esophageal squamous
cell carcinoma
174 (0.02) 33 (0.01) 0.57 (0.39–0.83) 24 (0.02) 0.71 (0.46–1.09) 9 (0.01) 0.38 (0.19–0.75)
*Adjusted for age, parity, hysterectomy, thrombotic events, diabetes mellitus, obesity, smoking-related diseases, alcohol-related diseases, and oste-
oporosis (all but osteoporosis were used for matching).
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for different age groups in relation to MHT prescription. The
lack of any increased risk of gastric adenocarcinoma or
esophageal squamous cell carcinoma with longer duration of
MHT argues in favor of non-hormonal inﬂuence. However,
the matching on many health-related factors intended to
counteract such bias, and the results of this study are well in
line with all three meta-analyses on the topic. These meta-
analyses have found decreased risk estimates of esophageal
adenocarcinoma (odds ratio 0.75, 95% CI 0.58–0.98, 5 studies
included),12 gastric adenocarcinoma (risk ratio 0.77, 95% CI
0.64–0.92, 7 studies included),13 and esophageal squamous cell
carcinoma (risk ratio 0.68, 95% CI 0.48–0.96, 4 studies includ-
ed).14 Moreover, presence of estrogen receptors have repeatedly
been found in both esophageal and gastric adenocarcinoma
cells, and treatment with ligands binding to selective estrogen
receptors could inhibit cell growth and induce apoptosis in
esophageal adenocarcinoma.30–37 It has also been suggested that
sex hormones inhibit cell growth in gastric adenocarcinoma and
esophageal squamous cell carcinoma.38–40
Progesterone receptors have been found in gastric adeno-
carcinoma in some studies but to a similar extent as in nor-
mal mucosa.33,41–43 Androgen receptors have been identiﬁed
in esophageal adenocarcinoma and esophageal squamous cell
carcinoma, while these receptors have been inconsistently
found in gastric adenocarcinoma.43–45 Thus, sex hormonal
inﬂuence might play a key role in explaining the ﬁndings of
this study.
There is a need for more large-scale studies with long
follow-up and adjustment for lifestyle factors before a causal
relation between sex hormonal therapy and cancer prevention
can be established. If the ﬁndings of the current study are
supported by such research, they would encourage research
examining new prevention strategies using sex hormonal
therapy in high-risk individuals of esophageal or gastric can-
cers and of hormonal adjuvant therapy of these tumors.
In conclusion, this large population-based cohort study
with robust assessments of exposures and outcomes and
adjustment for several potential confounding factors found
that ever-users of MHT are at a decreased risk of esophageal
adenocarcinoma, gastric adenocarcinoma and esophageal
squamous cell carcinoma. These ﬁndings might potentially be
explained by sex hormonal effects, but this remains uncer-
tain, and more research is required to examine the mecha-
nisms behind these associations.
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